TY - JOUR
T1 - Prognostic factors for adult single cord blood transplantation among European and Japanese populations
T2 - the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study
AU - Kanda, Junya
AU - Hayashi, Hiromi
AU - Ruggeri, Annalisa
AU - Kimura, Fumihiko
AU - Volt, Fernanda
AU - Takahashi, Satoshi
AU - Labopin, Myriam
AU - Kako, Shinichi
AU - Tozatto-Maio, Karina
AU - Yano, Shingo
AU - Sanz, Guillermo
AU - Uchida, Naoyuki
AU - Van Lint, Maria Teresa
AU - Kato, Seiko
AU - Mohty, Mohamad
AU - Forcade, Edouard
AU - Kanamori, Heiwa
AU - Sierra, Jorge
AU - Ohno, Yuju
AU - Saccardi, Riccardo
AU - Fukuda, Takahiro
AU - Ichinohe, Tatsuo
AU - Takanashi, Minoko
AU - Rocha, Vanderson
AU - Okamoto, Shinichiro
AU - Nagler, Arnon
AU - Atsuta, Yoshiko
AU - Gluckman, Eliane
N1 - Funding Information:
Conflict of interest JK reports honoraria from Chugai Pharmaceutical Co., Ltd., Celgene K.K., Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Limited., Astellas Pharma Inc., Bristol-Myers Squibb, Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., JCR Pharmaceuticals Co., Ltd., Pfizer Japan Inc., Kyowa Kirin, and MSD Pharma, outside the submitted work. GS reports grants, honoraria, advisory role, and travel accommodations expenses from Celgene, advisory role from Abbvie, Helsinn Healthcare, Janssen, Roche, Amgen, Boehringer Ingelheim, and Novartis, and travel accommodations expenses from Takeda and Gilead Sciences, outside the submitted work. EF reports grants from Neovii, outside the submitted work. SKako reports honoraria from Chugai Pharmaceutical Co., Ltd., Celgene K.K., Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Limited., Astellas Pharma Inc., Bristol-Myers Squibb, Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Pfizer Japan Inc., outside the submitted work. JS reports and Advisory and Speaker’s Bureau for Novartis, Pfizer, Celgene, Daiichi-Sankyo and Jazz Pharmaceuticals. SY reports grants from Kyowa Kirin, Astellas Pharma, Chugai Pharma, Mochida Pharma, Lilly Pharma, Takeda Pharma, MSD Pharma, Pfizer, Dai Nippon Sumitomo Pharma, and Ono Pharma, outside the submitted work.YA reports honoraria from CHUGAI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd, Bristol-Myers Squibb Co., Ltd, Yakult Honsha Co., Ltd., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical Co., Ltd, and Mochida Pharmaceutical Co., Ltd, outside the submitted work. Other authors declare that they have no conflict of interest.
Funding Information:
Acknowledgements This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development, AMED (YA and JK) and JSPS KAKENHI Grant Number 18K08325 (JK).
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Large differences in patient and transplant backgrounds make it difficult to identify consistent prognostic factors of unrelated cord blood transplantation (UCBT) among different populations. Thus, we performed a collaborative study between Eurocord/ALWP-EBMT and JSHCT/JDCHCT. Adults with acute leukaemia who underwent a single UCBT were eligible. In total, 3764 and 1027 patients of the JSHCT/JDCHCT and Eurocord/ALWP-EBMT registries, respectively, were included. The median ages of the Japanese and European cohorts were 51 and 38 years, respectively. Three or more HLA mismatches were more frequently observed in the Japanese cohort. The median total nucleated cell (TNC) counts were 2.58 and 3.51 × 107/kg in the Japanese and European cohorts, respectively. Anti-thymocyte globulin was used in only 2% of the Japanese cohort compared with 65% of the European cohort. The 3-year overall survival (OS) was 41% in JSHCT/JDCHCT and 33% in Eurocord/ALWP-EBMT. In the multivariate analysis, TNC dose and HLA matching had no significant effect on OS in either cohort, whereas year of transplantation, age, and refined disease risk index affected OS in both cohorts. Despite considerable differences in characteristics between the Japanese and European cohorts, we observed similar prognostic factors affecting UCBT outcomes in adult patients with acute leukaemia in both registries.
AB - Large differences in patient and transplant backgrounds make it difficult to identify consistent prognostic factors of unrelated cord blood transplantation (UCBT) among different populations. Thus, we performed a collaborative study between Eurocord/ALWP-EBMT and JSHCT/JDCHCT. Adults with acute leukaemia who underwent a single UCBT were eligible. In total, 3764 and 1027 patients of the JSHCT/JDCHCT and Eurocord/ALWP-EBMT registries, respectively, were included. The median ages of the Japanese and European cohorts were 51 and 38 years, respectively. Three or more HLA mismatches were more frequently observed in the Japanese cohort. The median total nucleated cell (TNC) counts were 2.58 and 3.51 × 107/kg in the Japanese and European cohorts, respectively. Anti-thymocyte globulin was used in only 2% of the Japanese cohort compared with 65% of the European cohort. The 3-year overall survival (OS) was 41% in JSHCT/JDCHCT and 33% in Eurocord/ALWP-EBMT. In the multivariate analysis, TNC dose and HLA matching had no significant effect on OS in either cohort, whereas year of transplantation, age, and refined disease risk index affected OS in both cohorts. Despite considerable differences in characteristics between the Japanese and European cohorts, we observed similar prognostic factors affecting UCBT outcomes in adult patients with acute leukaemia in both registries.
UR - http://www.scopus.com/inward/record.url?scp=85070791227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070791227&partnerID=8YFLogxK
U2 - 10.1038/s41375-019-0534-5
DO - 10.1038/s41375-019-0534-5
M3 - Article
C2 - 31409921
AN - SCOPUS:85070791227
VL - 34
SP - 128
EP - 137
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 1
ER -
